Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0918 USD
−131.00 K USD
7.79 M USD
3.70 M
About International Stem Cell Corp.
Sector
Industry
CEO
Andrey Semechkin
Website
Headquarters
San Diego
Founded
2005
FIGI
BBG000BNH2G6
International Stem Cell Corp. operates as a research and development company for the therapeutic market. It focuses on advancing potential clinical applications of human parthenogenetic stem cells for the treatment of various diseases of the central nervous system and liver diseases. The firm operates through three segments: Therapeutic Market, Biomedical Market and Anti-Aging Market. The Biomedical Market segment markets and sells primary human cell research products with two product categories, cells and media. The Anti-Aging market segment markets and sells a line of skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are to spas, salons and other skincare providers. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich and Gregory S. Keller in June 2005 and is headquartered in San Diego, CA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ISCO is 0.0800 USD — it hasn't changed in the past 24 hours. Watch International Stem Cell Corp. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange International Stem Cell Corp. stocks are traded under the ticker ISCO.
ISCO stock has fallen by −20.00% compared to the previous week, the month change is a 16.36% rise, over the last year International Stem Cell Corp. has showed a −28.57% decrease.
ISCO reached its all-time high on Feb 1, 2007 with the price of 522.3890 USD, and its all-time low was 0.0460 USD and was reached on Feb 14, 2024. View more price dynamics on ISCO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ISCO stock is 0.00% volatile and has beta coefficient of 1.14. Track International Stem Cell Corp. stock price on the chart and check out the list of the most volatile stocks — is International Stem Cell Corp. there?
Today International Stem Cell Corp. has the market capitalization of 640.35 K, it has decreased by −39.29% over the last week.
Yes, you can track International Stem Cell Corp. financials in yearly and quarterly reports right on TradingView.
International Stem Cell Corp. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ISCO net income for the last quarter is −125.00 K USD, while the quarter before that showed 62.00 K USD of net income which accounts for −301.61% change. Track more International Stem Cell Corp. financial stats to get the full picture.
No, ISCO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has 29.00 employees. See our rating of the largest employees — is International Stem Cell Corp. on this list?
Like other stocks, ISCO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade International Stem Cell Corp. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So International Stem Cell Corp. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating International Stem Cell Corp. stock shows the sell signal. See more of International Stem Cell Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.